Hormone replacement therapy: One-year follow up of DNA damage

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 585, Issue 1-2, 2005, Pages 14-20

  Casella, Marta ^a   Manfredi, Samantha ^b   Andreassi, Maria Grazia ^b   Vassalle, Cristina ^a   Prontera, Concetta ^a   Simi, Silvana ^a   Maffei, Silvia ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b G Pasquinucci Hospital   (United States)

Author keywords

Genotoxicity; Hormone replacement therapy (HRT); Menopause; Micronuclei; Steroids

Indexed keywords

BIOLOGICAL MARKER; DYDROGESTERONE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE;

ARTICLE; BLOOD SAMPLING; DNA DAMAGE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MEASUREMENT; MENOPAUSE; MONITORING; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; DNA DAMAGE; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; LYMPHOCYTES; MICRONUCLEUS TESTS; MIDDLE AGED; POSTMENOPAUSE;

EID: 22144436261     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2005.03.014     Document Type: Article

References (34)

1. H.D. Nelson, L.L. Humphrey, P. Nygren, S.M. Teutsch, and J.D. Allan Postmenopausal hormone replacement therapy: scientific review JAMA 288 2002 872 881
2. C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, and L. Brinton Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 283 2000 485 491
3. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial, JAMA 288 (2002) 321-333.
4. B.E. Henderson, and H.S. Feigelson Hormonal carcinogenesis Carcinogenesis 21 2000 427 433
5. A. Inoh, K. Kamiya, Y. Fujii, and K. Yokoro Protective effects of progesterone and tamoxifen in estrogen-induced mammary carcinogenesis in ovariectomized W/Fu rats Jpn. J. Cancer Res. 76 1985 699 704
6. P.K. Siiteri, J.A. Nisker, and G.L. Hammond Hormonal basis of risk factors for breast and endometrial cancer S. Iacobelli King RJB H.R. Lindner M.E. Lippman Hormones and Cancer 1980 Raven Press New York 499 505
7. D.L. Davis, N.T. Telang, M.P. Osborne, and H.L. Bradlow Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer Environ. Health Perspect. 105 1997 571 576
8. G. Castoria, M.V. Barone, M. Di Domenico, A. Bilancio, D. Ametrano, A. Migliaccio, and F. Auricchio Non-transcriptional action of oestradiol and progestin triggers DNA synthesis EMBO J. 18 1999 2500 2510
9. J.G. Liehr Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev. 21 2000 40 45
10. M.D. Evans, J.M. Butler, K. Nicoll, M.S. Cooke, and J. Lunec 17 Beta-oestradiol attenuates nucleotide excision repair FEBS Lett. 535 2003 153 158.
11. B. Vogelstein, and Kinzler KW K.W. Kinzler B. Vogelstein The genetic basis of human cancer 1998 McGraw-Hill 15 16
12. J.D. Tucker, and R.J. Preston Chromosome aberration, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment Mutat. Res. 365 1996 147 159
13. L. Hagmar, S. Bonassi, U. Stromberg, A. Brogger, L.S. Knudsen, H. Norppa, and C. Reuterwall Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH) Cancer Res. 58 1998 4117 4121
14. S. Bonassi, L. Hagmar, U. Stromberg, A.H. Montagud, H. Tinnerberg, A. Forni, P. Heikkila, S. Wanders, P. Wilhardt, I.L. Hansteen, L.E. Knudsen, and H. Norppa Chromosomal aberrations predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health Cancer Res. 60 2000 1619 1625
15. M. Fenech The cytokinesis-block micronucleus technique and its application to genotoxicity studies in human populations Environ. Health Perspect. 101 1993 101 107
16. M. Fenech Chromosomal biomarkers of genomic instability relevant to cancer Drug Discov. Today 7 2002 1128 1137
17. A. Rothfuss, P. Schutz, S. Bochum, T. Volm, E. Eberhardt, R. Kreienberg, W. Vogel, and G. Speit Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families Cancer Res. 60 2000 390 394
18. S. Maffei, A. Clerico, G. Iervasi, M. Nannipieri, S. Del Ry, D. Giannessi, and L. Donato Circulating levels of cardiac natriuretic hormones measured in women during menstrual cycle J. Endocrinol. Invest. 22 1999 1 5
19. M. Casella, M. Lucarelli, M. Simili, P. Beffy, R. Del Carratore, F. Minichilli, C. Chisari, and S. Simi Spontaneous chromosome loss and colcemid resistance in lymphocytes from patients with myotonic dystrophy type 1 Cytogenet. Genome Res. 100 2003 224 229
20. M.G. Andreassi, E. Picano, S. Del Ry, N. Botto, M.G. Colombo, D. Giannessi, V. Lubrano, C. Vassalle, and A. Biagini Chronic long-term nitrate therapy: possible cytogenetic effect in humans? Mutagenesis 16 2001 517 521
21. J.G. Leihr Genotoxic effects of estrogens Mutat. Res. 238 1990 269 276
22. V.S. Dhillon, and I.K. Dhillon Genotoxicity evaluation of estradiol Mutat. Res. 345 1995 87 95
23. B.S. Hundal, V.S. Dhillon, and I.S. Sidhu Genotoxic potential of estrogens Mutat. Res. 389 1997 173 218
24. R. Lang, and U. Redmann Non-mutagenicity of some sex hormones in the Ames salmonella/microsome mutagenicity test Mutat. Res. 67 1979 361 365
25. D. Roy, and J.G. Liehr Estrogen, DNA damage and mutations Mutat. Res. 424 1999 107 115
26. M.E. Ahmad, G.G. Shadab, A. Hoda, and M. Afzal Genotoxic effects of estradiol-17beta on human lymphocyte chromosomes Mutat. Res. 466 2000 109 115
27. H. McQuarrie, C.D. Scott, H. Ellsworth, J. Harris, and R. Stone Cytogenetic studies on women using oral contraceptives and their progeny Am. J. Obstet. Gynec. 108 1970 659 665
28. N.P. Bishun, N. Smith, D. Williams, and E. Gristwood Chromosomal satellite association in women using oral contraceptives and their progeny Cytologia 37 1972 639 642
29. L. Shapiro, Z. Graves, and Z. Hirschhorn Oral contraceptives and in vivo cytogenetic studies Obstet. Gynec. 39 1972 190 192
30. L.G. Littlefild, and J.B. Mailhes Comparison of chromosome breakage in lymphocytes and fibroblasts from control women taking oral contraceptives Fertil. Steril. 26 1975 828 832
31. R. Ghosh, and P.K. Ghosh Sister chromatid exchanges in the lymphocytes of control women, pregnant women, and women taking oral contraceptives: effects of cell culture temperature Environ. Mol. Mutagen. 12 1998 179 183
32. N. Bukvic, F. Susca, D. Bukvic, M. Fanelli, and G. Guanti 17-Alpha-ethinylestradiol and norgestrel in combination induce micronucleus increases and aneuploidy in human lymphocyte and fibroblast cultures Teratog. Carcinog. Mutagen. 20 2000 147 159
33. F. Kayikcioglu, M. Gunes, V. Baltaci, M. Kocak, I. Alpas, and A. Haberal Sister-chromatid exchange frequencies in postmenopausal hormone replacement patients Mutat. Res. 452 2000 37 39
34. F.I. Sahin, I. Sahin, M.A. Ergun, and O.F. Saracoglu Effects of estrogen and alendronate on sister chromatid exchange (SCE) frequencies in postmenopausal osteoporosis patients Int. J. Gynaecol. Obstet. 71 2000 49 52